Price
$3.53
Decreased by -5.36%
Dollar Volume
10.63 M
ADR%
19.79
Market Cap.
13.19 M
Shares Float
1.33 M
Shares Outstanding
3.74 M
Beta
0.56
Price / Earnings
4.06
BPR
9.66
20D Range
3.09 6.30
50D Range
1.18 10.00
200D Range
1.18 48.80
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 10, 22 -1.40 0.20
Decreased by -800.00%
Aug 9, 22 1.80 -2.60
Increased by +169.23%
Mar 31, 22 1.00 -2.60
Increased by +138.46%
Nov 15, 21 10.80 -2.40
Increased by +550.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-21.49 M
Decreased by -217.44%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
2.94 M
Increased by +112.53%
Increased by +N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
1.56 M
Increased by +109.65%
Increased by +N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
1.04 M
Increased by +155.09%
Increased by +N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
18.30 M
Increased by +646.28%
Increased by +N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-23.46 M
Decreased by -8.87 K%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-16.20 M
Decreased by -580.25%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-1.88 M
Increased by +92.65%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.